Skip to main content
Clinical Trials/NCT02631850
NCT02631850
Completed
N/A

Video Game Rehabilitation for Outpatient Stroke (VIGoROUS): A Multi-center Comparative Effectiveness Trial of In-home Gamified Constraint-induced Movement Therapy for Rehabilitation of Chronic Upper Extremity Hemiparesis.

Ohio State University5 sites in 1 country193 target enrollmentNovember 2015

Overview

Phase
N/A
Intervention
Not specified
Conditions
Stroke
Sponsor
Ohio State University
Enrollment
193
Locations
5
Primary Endpoint
Wolf Motor Function Test
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The current proposal aims to conduct a multi-site randomized controlled trial comparing virtual-reality gaming delivery of Constraint Induced Movement therapy (CI therapy) with (1) traditional clinic-based CI therapy of equal total active therapy duration and (2) a control group equating the dose of in-person therapy. Individuals with chronic stroke will be randomized to one of four different interventions: (1) traditional clinic-based CI therapy (35 therapist/client contact hours), (2) therapist-as-consultant virtual reality CI therapy (5 therapist/client contact hours in the clinic and 15 hours of independent game play at home), (3) therapist-as-consultant virtual reality CI therapy with additional therapist contact via telerehabilitation (5 therapist/client contact hours in the clinic, 2.6 therapist contact hours via teleconference, and 15 hours of independent game play in the home), and (4) 5 hours of standard occupational therapy (OT) / physical therapy (PT). After 6-month follow-up, individuals assigned to standard OT/PT will cross over to a modified gaming therapy condition (a stand-alone application of the rehabilitation game without additional therapist contact).

Detailed Description

Detailed study description published in BMC Neurology (2017).

Registry
clinicaltrials.gov
Start Date
November 2015
End Date
December 31, 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Deborah S Larsen

Professor

Ohio State University

Eligibility Criteria

Inclusion Criteria

  • Males, females, or any gender identity 18 years of age or older
  • Experienced a stroke resulting in mild-to-moderate hemiparesis at least six months prior to enrollment (suggested range of motion (ROM) criteria includes: 45° shoulder abduction and flexion, 20° elbow extension, 20° wrist extension, and 10° extension of thumb and finger)
  • Have preserved ability to comprehend and participate in basic elements of the therapy

Exclusion Criteria

  • Concurrent participation in other experimental trials for motor dysfunction treatment
  • Receiving Botox therapy currently or in the past 3 months
  • Have medical conditions that would place volunteers at higher risk of adverse events (e.g., renal disease, frailty, pregnancy, dementia, severe pain, end-stage/degenerative diseases)
  • Have received intensive upper-extremity rehabilitation in the chronic phase post-stroke

Outcomes

Primary Outcomes

Wolf Motor Function Test

Time Frame: 0 to 1 months

Assesses the time to complete 15 standardized tasks (e.g., folding a towel, stacking checkers, placing hand on top of a box). Items that cannot be accomplished score 120 seconds. Times are natural log transformed to reflect proportional improvement (approximate % change) and correct for skew. On the log transformed scale, -.22 reflects normal ability, 4.79 = can't accomplish task. For improvement in mean log transformed performance time, -4.79 = best possible improvement, 0 = no improvement, positive scores = worsening. A proportional improvement of 16% (mean log transformed performance time change = -.17) is considered clinically meaningful.

Motor Activity Log Quality of Movement Scale

Time Frame: 0 to 1 months

Assessment evaluates the amount and quality of everyday arm use. The scale consists of 28 activities of daily living (e.g., washing hands, drinking from a cup). Participants self-report on an 11-point scale (0-5 with half-point increments, 0=not attempted to 5=attempted with normal movement). The total score on the measure reflects the mean of the individual item scores. A change of 1.0 on the scale is considered clinically meaningful.

Secondary Outcomes

  • Semmes-Weinstein Monofilament Test(0 to 1 months)
  • Change in Neuro-Quality of Life (Neuro-QOL)(0 to 1 months)
  • Bilateral Activity Monitors(0 to 1 month)
  • 9 Hole Peg Test(0 to 1 months)
  • Change in Brief Kinesthesia Test (BKT)(0 to 1 months)

Study Sites (5)

Loading locations...

Similar Trials